Once-Weekly 1.6 mg/m(2) Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy

類似資料

• Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
  著者:: Yao, Rongxin, 等
  出版事項: (2019)
• The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
  著者:: He, Jingsong, 等
  出版事項: (2014)
• Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma
  著者:: Ghosh, Nilanjan, 等
  出版事項: (2011)
• Treatment of Newly Diagnosed Myeloma: Bortezomib-based Triplet
  著者:: Rajan, Archana M., 等
  出版事項: (2016)
• Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
  著者:: Ashrafi, Farzaneh, 等
  出版事項: (2020)